Finanzen von Vericel Corp (VCEL)VCELVericel Corp

Vericel Corporation (VCEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MACI, accounting for 84.6% of total sales, equivalent to $65.51M. Other significant revenue streams include Epicel and NexoBrid. Understanding this composition is critical for investors evaluating how VCEL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Vericel Corporation maintains a gross margin of 72.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.56%, while the net margin is 2.85%. These profitability ratios, combined with a Return on Equity (ROE) of 7.16%, provide a clear picture of how effectively VCEL converts its operational activities into shareholder value.

In the context of the broader market, VCEL competes directly with industry leaders such as BRVE and ZYME. With a market capitalization of $2.26B, it holds a leading position in the sector. When comparing efficiency, VCEL's gross margin of 72.82% stands against BRVE's N/A and ZYME's 100.00%. Such benchmarking helps identify whether Vericel Corporation is trading at a premium or discount relative to its financial performance.

Vericel has shown strong revenue growth, with Q2 2026 revenue of $77.5 million, a 22.5% increase year-over-year, and a gross margin of approximately 75%. The company has also raised its full-year revenue guidance to $330 million to $340 million, reflecting confidence in continued growth.